**Title: OctreoScan® scintigraphy for gastro-entero-pancreatic (GEP)**

**neuroendocrine tumours August 1999**

**Agency:** Medicare Services Advisory Committee (MSAC) Commonwealth Department of Health and Age ing GPO Box 9848 Canberra ACT 2601 Australia [**http://www.msac.gov.au**](http://www.msac.gov.au/)

**Reference: MSAC application 1003. Assessment report ISSN 1443-7120**

**Aim**

To assess the safety and effectiveness of the service and under what circumstances public funding should be supported for the service.

**Conclusions and results**

*Safety* OctreoScan is safe at recommended doses.

*Effectiveness* OctreoScan has the advantage of being able to image the whole body. It can detect extrapancreatic tumours and metastatic lesions outside of the abdomen and chest, and MEN-1 tumours. It is less sensitive in the detection of insulinomas.

Sensitivity and specificity could not be determined as test results were not

compared in blind fashion with an acceptable ‘gold standard’. There is some evidence that OctreoScan changes patient management, but no evidence to suggest increased cure rates and survival time.

*Cost-effectiveness* It was not possible to assess cost-effectiveness due to lack of validated data on test accuracy and impact on clinical outcomes.

**Recommendations**

Public funding should be supported for OctreoScan where:

biochemical evidence indicates a GEP neuroendocrine tumour and conventional

radiology produces negative or equivocal structural imaging; or

biochemical and conventional imaging indicates a surgically amenable disease in order to

rule out further metastatic disease.

However, there is insufficient evidence to support public funding for octreotide therapy as a viable therapeutic option.

**Method**

MSAC conducted a systematic review of the biomedical literature from 1989 to 1999 by

accessing biomedical electronic databases, the Internet and international health technology agency websites. Reference lists of reviews and other articles were also searched. Data was also available from unpublished trials conducted by a manufacturer of the technology (Mallinckrodt Medical Petten).

Prepared by the Centre for Clinical Effectiveness, Australia